JP2021519262A5 - - Google Patents
Info
- Publication number
- JP2021519262A5 JP2021519262A5 JP2020551269A JP2020551269A JP2021519262A5 JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5 JP 2020551269 A JP2020551269 A JP 2020551269A JP 2020551269 A JP2020551269 A JP 2020551269A JP 2021519262 A5 JP2021519262 A5 JP 2021519262A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- use according
- indole
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1850380-5 | 2018-04-05 | ||
| SE1850380 | 2018-04-05 | ||
| PCT/SE2019/050312 WO2019194738A1 (en) | 2018-04-05 | 2019-04-04 | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519262A JP2021519262A (ja) | 2021-08-10 |
| JP2021519262A5 true JP2021519262A5 (enExample) | 2022-04-07 |
| JP7372253B2 JP7372253B2 (ja) | 2023-10-31 |
Family
ID=68101552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551269A Active JP7372253B2 (ja) | 2018-04-05 | 2019-04-04 | 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11590130B2 (enExample) |
| EP (1) | EP3773592B1 (enExample) |
| JP (1) | JP7372253B2 (enExample) |
| CN (1) | CN111936143A (enExample) |
| CA (1) | CA3095709A1 (enExample) |
| WO (1) | WO2019194738A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249052A1 (zh) | 2015-03-06 | 2018-10-26 | BeyondSpring Pharmaceuticals Inc. | 治疗与ras突变相关的癌症的方法 |
| US10912748B2 (en) | 2016-02-08 | 2021-02-09 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
| CN109475524A (zh) | 2016-06-06 | 2019-03-15 | 万春药业公司 | 用于减少中性粒细胞减少症的组合物和方法 |
| WO2018129381A1 (en) | 2017-01-06 | 2018-07-12 | Beyondspring Pharmaceuticals, Inc. | Tubulin binding compounds and therapeutic use thereof |
| KR20190109479A (ko) | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| KR20230006568A (ko) * | 2020-05-04 | 2023-01-10 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법 |
| EP4319751A4 (en) | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| JP2026509292A (ja) * | 2023-03-10 | 2026-03-17 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 腫瘍学的併用療法及びその使用方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2338487T1 (sl) | 2006-01-17 | 2014-01-31 | Abbott Laboratories | Kombinacijska terapija z inhibitorji PARP |
| RU2009147819A (ru) | 2007-05-25 | 2011-06-27 | Астразенека Аб (Se) | Комбинация ингибиторов снк и parp для лечения злокачественных новообразований |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| AU2008333786A1 (en) | 2007-12-07 | 2009-06-11 | Bipar Sciences, Inc. | Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors |
| DK2271626T3 (en) * | 2008-03-27 | 2015-02-23 | Janssen Pharmaceutica Nv | TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN |
| WO2009118384A1 (en) * | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| AR075239A1 (es) | 2009-02-04 | 2011-03-16 | Bipar Sciences Inc | Tratamiento del cancer de pulmon con un inhibidor de la parp en combinacion con un inhibidor de un factor de crecimiento. composicion farmaceutica. uso |
| US8541417B2 (en) * | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| WO2011151423A1 (en) * | 2010-06-04 | 2011-12-08 | Exonhit S.A. | Substituted isoquinolines and their use as tubulin polymerization inhibitors |
| MX2013010898A (es) * | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
| TWI577693B (zh) * | 2011-05-31 | 2017-04-11 | 江蘇康緣藥業股份有限公司 | 聚（ａｄｐ-核糖）聚合酶之三環抑制劑 |
| US9132120B1 (en) | 2012-04-02 | 2015-09-15 | Stc.Unm | Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers |
| EP2984184B1 (en) | 2013-04-09 | 2020-11-25 | The Board of Trustees of the University of Illionis | Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer |
| US10195175B2 (en) * | 2015-06-25 | 2019-02-05 | Immunomedics, Inc. | Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors |
| WO2017013593A1 (en) * | 2015-07-22 | 2017-01-26 | Lupin Limited | Isoquinolinone derivatives as parp inhibitors |
| US20180344725A1 (en) * | 2015-11-20 | 2018-12-06 | Hoyun Lee | Quinolone chalcone compounds and uses thereof |
| MX387726B (es) * | 2016-06-24 | 2025-03-18 | Univ California | Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina útiles para el tratamiento del cáncer. |
-
2019
- 2019-04-04 CA CA3095709A patent/CA3095709A1/en active Pending
- 2019-04-04 US US16/981,232 patent/US11590130B2/en active Active
- 2019-04-04 EP EP19781419.7A patent/EP3773592B1/en active Active
- 2019-04-04 WO PCT/SE2019/050312 patent/WO2019194738A1/en not_active Ceased
- 2019-04-04 CN CN201980024687.3A patent/CN111936143A/zh active Pending
- 2019-04-04 JP JP2020551269A patent/JP7372253B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024530495A5 (enExample) | ||
| JP2013505249A5 (enExample) | ||
| JP2010528026A5 (enExample) | ||
| JP2015232006A5 (enExample) | ||
| RU2013128612A (ru) | Соли и кристаллические формы индуцирующего апоптоз агента | |
| JP2023539715A5 (enExample) | ||
| JP2017516784A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| JP2007511504A5 (enExample) | ||
| HRP20171902T1 (hr) | Farmaceutski oblik za doziranje za oralnu primjenu inhibitora iz obitelji bcl-2 | |
| JP2013544804A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2011527334A5 (enExample) | ||
| JP2015509540A5 (enExample) | ||
| RU2012115851A (ru) | Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2 | |
| JP2020504716A5 (enExample) | ||
| JP2021534158A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| JP2014514317A5 (enExample) | ||
| JP2008521928A5 (enExample) | ||
| JP2008535803A5 (enExample) | ||
| RU2011148521A (ru) | Соль авт-263 и ее формы в твердом состоянии | |
| JP2012520321A5 (enExample) | ||
| JP2014530243A (ja) | Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物 | |
| JP2010527984A5 (enExample) |